Shandong Jiangzheng Biotechnology Co., Ltd. was formerly known as Linyi Tianli Biochemical Co., Ltd. Tianli Biochemical was founded in 1998 and began to devote itself to the production and technological research and development of CDCA in 2001, focusing on the biological extraction of bile acid series product projects, gradually growing into the largest CDCA manufacturer in China. For many years, Tianli has been widely praised internationally for its excellent product quality and excellent service.
     Shandong Jiangzheng Biotechnology Co., Ltd. was established on June 6, 2019, and its business scope involves biotechnology research and development; Production and sales of bile acid series products; Import and export of goods and technology. The company has invested 312 million yuan to construct a series of bio extracted bile acid product projects. The project is located on the south side of the west section of Huaihai Road, covering a total area of 120 acres. It plans to build 6 production workshops, 1 cold storage and initial processing workshop, 1 warehouse, 1 tank area, and 1 sewage treatment station, as well as supporting public auxiliary facilities such as fire water tanks, accident water tanks, circulating water tanks, transformer and distribution rooms, as well as office and living buildings such as research and development centers. The total construction area is 35000 square meters. After the project is fully completed and put into operation, it can produce 460 tons of chenodeoxycholic acid, 300 tons of ursodeoxycholic acid, 300 tons of bile acid, and 500 tons of mixed bile acid annually.
      Goose deoxycholic acid (CDCA), also known as 3 α， seven α- Dihydroxy-5 β- Bile alkanoic acid is a natural primary bile acid that is widely present in the bile of humans, livestock, and poultry. It is the main organic component in the bile of poultry such as chickens, ducks, and geese. Since the 1970s, chenodeoxycholic acid has been mainly used in clinical practice to treat gallstone diseases and other liver and gallbladder diseases, and its application in medicine has been highly valued. The application value of chenodeoxycholic acid in medicine has led to the gradual improvement of its preparation methods. In recent years, there has been an increasing amount of research on derivatives of chenodeoxycholic acid, which has extended to various fields such as biomedicine, molecular recognition, and functional materials. Especially in the field of biomedicine, chenodeoxycholic acid derivatives have shown broad application prospects. In addition, chenodeoxycholic acid also has pharmacological effects such as antibacterial, anti-inflammatory, antipyretic, and immune regulation. It has certain effects on asthma, osteoarthritis, brain tendon xanthoma, and insulin tolerance. Therefore, its clinical application scope is constantly expanding.
      Goose deoxycholic acid was initially used as a litholytic drug in clinical practice, and its derivative, obycholic acid, has unique efficacy in the treatment of primary biliary cirrhosis and non-alcoholic fatty liver disease. Goose deoxycholic acid, as a member of steroid compounds, has properties similar to bile acid. Amphiphilicity, acid-base properties, and characteristics derived from living organisms have aroused the interest of many researchers in the fields of biomedicine and chemistry. Due to its ease of modification, its derivatives have broad applications in asymmetric synthesis, molecular recognition, biomedical and pharmaceutical fields, and polymer biomaterials. Different application fields use different modification methods, which lay the foundation for further modification and facilitate the emergence of new modification methods. In recent years, research has found that in the dissolution of gallstones, the isomer of ursodeoxycholic acid (UDCA) has a better clinical application effect and no side effects. Goose deoxycholic acid can also be used as a raw material for synthesizing ursodeoxycholic acid, a widely used drug for the treatment of gallstone diseases in clinical practice.
      Ursodeoxycholic acid (3) α, seven β- 2-Dihydroxy-25 β 2-Bilecanoic acid, abbreviated as UDCA, is the main active ingredient in the precious traditional Chinese medicine bear bile. It is used in clinical practice to treat various gallstone diseases, as well as acute and chronic liver diseases, and has good effects. The traditional Chinese medicine preparations of bear bile have been widely developed and utilized in China and Southeast Asia. Natural ursodeoxycholic acid comes from bear bile, and the practice of killing bears to extract bile and extracting bear bile from the bear body through drainage techniques has been banned by national orders. Currently, ursodeoxycholic acid can only be synthesized through chemical methods. Initially, people synthesized ursodeoxycholic acid from bile of pigs, cows, and sheep using bile acids, deoxycholic acid, and other raw materials. However, this method has multiple reaction steps, complex process, low yield, and is difficult to produce on a large scale. In recent years, research has found that the synthesis process of ursodeoxycholic acid using chenodeoxycholic acid extracted from the bile of chickens, ducks, geese and other poultry as raw materials is relatively simple and has a high yield, which is not easy to cause environmental pollution. At present, ursodeoxycholic acid sold in the market is mainly synthesized using this method. The traditional process of extracting goose deoxycholic acid from the bile of chickens, ducks, and geese includes steps such as bile saponification, acidification, removal of alcohol insoluble substances, defatting, generation of barium salts, and removal of barium. The process is complex, the yield is low, and industrial application is difficult. Poultry gallbladder is small and difficult to manually break and extract bile.
      As the production scale of poultry product processing enterprises continues to increase, the production of bitter bile has surged. Abandoning bitter bile as waste will not only cause resource waste, but also cause environmental problems. In order to solve this problem, some poultry product processing enterprises have started collecting and preserving bitter bile. Goose deoxycholic acid is the main organic component in bitter galls such as chickens, ducks, and geese. If goose deoxycholic acid is extracted from it, it will produce considerable economic benefits. As a raw material for synthesizing ursodeoxycholic acid, it can create significant social value. In recent years, the incidence rate of cholesterol gallstones has been rising due to unhealthy and unbalanced eating habits in modern society. The continuous expansion of the population affected by cholesterol gallstones has led to an increasing market demand for chenodeoxycholic acid and chenodeoxycholic acid, which will stimulate the supply of chenodeoxycholic acid and chenodeoxycholic acid markets.